IVD China last week: YHLO, Autobio, BGI and Kindstar Global

YHLO's Revenue Surges 52.28% in H1 2024

As of the first half of 2024, the business of YHLO Biotech has covered more than 110 countries around the world, and the revenue of overseas non-COVID-related business exceeded RMB 102 million, increase by 52.28% year-on-year.

In the second half of 2024, the company will unswervingly continue to implement the dual-wheel-drive overseas strategy of developed countries+emerging markets, and at the same time, further tilt towards international marketing in terms of the company's strategic resources.

Autobio Gains IVDR CE Mark for 234 Products

Autobio has recently received the IVDR CE certification for 234 additional products, expanding its IVDR portfolio to 326 products. This certification, granted by TÜV SÜD, covers key areas such as immunology, microbiology, and molecular diagnostics, reinforcing Autobio's leadership in the European market.

Kazakhstan Delegation Visits BGI Group for Strategic Cooperation

On September 19, 2024, Kunsulu Zakarya, Advisor to the President of Kazakhstan on Science, Technology and Innovation Affairs, and Akmaral Alnazarova, Minister of Health of Kazakhstan, led a delegation to visit BGI Group.

Members of the delegation came from the Ministry of Health of Kazakhstan, scientific research institutes, state-owned enterprises and so on. The visit facilitated in-depth discussions on joint scientific research, precision medicine, disease prevention, food security, and talent development, with the aim of strengthening bilateral cooperation in these key areas.

Kindstar Global in Talks to Acquire Two Biotech Firms

Kindstar announced on September 20, 2024 that it is in the process of negotiating for the acquisition of 100% equity interest in each of Kangchen Weiye Biotechnology and AnchorDx Inc. for a total consideration of approximately USD 31.3 million.

While discussions are ongoing, no binding agreements have been signed as of the announcement date. The acquisitions, once completed, are expected to bolster Kindstar’s capabilities in the biotech sector.